7.67
0.65%
-0.05
Maravai LifeSciences Holdings Inc stock is currently priced at $7.67, with a 24-hour trading volume of 1.28M.
It has seen a -0.65% decreased in the last 24 hours and a -12.44% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $7.73 pivot point. If it approaches the $7.36 support level, significant changes may occur.
Previous Close:
$7.72
Open:
$7.76
24h Volume:
1.28M
Market Cap:
$1.01B
Revenue:
$288.95M
Net Income/Loss:
$-119.03M
P/E Ratio:
13.47
EPS:
0.5695
Net Cash Flow:
$60.67M
1W Performance:
-0.78%
1M Performance:
-12.44%
6M Performance:
+16.57%
1Y Performance:
-46.62%
Maravai LifeSciences Holdings Inc Stock (MRVI) Company Profile
Name
Maravai LifeSciences Holdings Inc
Sector
Industry
Phone
858 546 0004
Address
10770 Wateridge Circle, Suite 200, San Diego
Maravai LifeSciences Holdings Inc Stock (MRVI) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-08-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
May-23-23 | Downgrade | Credit Suisse | Outperform → Neutral |
May-09-23 | Downgrade | Goldman | Buy → Neutral |
Jan-05-23 | Downgrade | UBS | Buy → Neutral |
Dec-14-22 | Initiated | Deutsche Bank | Buy |
Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
Nov-03-22 | Downgrade | BofA Securities | Buy → Neutral |
Aug-25-22 | Initiated | Credit Suisse | Outperform |
Aug-05-21 | Resumed | Credit Suisse | Outperform |
Dec-16-20 | Initiated | KeyBanc Capital Markets | Overweight |
Dec-15-20 | Initiated | BofA Securities | Buy |
Dec-15-20 | Initiated | Credit Suisse | Outperform |
Dec-15-20 | Initiated | Goldman | Buy |
Dec-15-20 | Initiated | Jefferies | Buy |
Dec-15-20 | Initiated | Robert W. Baird | Outperform |
Dec-15-20 | Initiated | Stifel | Buy |
Dec-15-20 | Initiated | William Blair | Outperform |
Dec-14-20 | Initiated | UBS | Buy |
View All
Maravai LifeSciences Holdings Inc Stock (MRVI) Latest News
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024
GlobeNewswire Inc.
BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday
Benzinga
Maravai LifeSciences Announces March 2024 Investor Conference Schedule
GlobeNewswire Inc.
Nasdaq Edges Lower; AXT Shares Surge After Q4 Results
Benzinga
Small-Cap Maravai LifeSciences' Q4 Outperforms Expectations, Analyst shows Optimism Around 2024 Guidance
Benzinga
Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Maravai LifeSciences Holdings Inc Stock (MRVI) Financials Data
Maravai LifeSciences Holdings Inc (MRVI) Revenue 2024
MRVI reported a revenue (TTM) of $288.94 million for the quarter ending December 31, 2023, a -67.28% decline year-over-year.
Maravai LifeSciences Holdings Inc (MRVI) Net Income 2024
MRVI net income (TTM) was -$119.03 million for the quarter ending December 31, 2023, a -154.05% decrease year-over-year.
Maravai LifeSciences Holdings Inc (MRVI) Cash Flow 2024
MRVI recorded a free cash flow (TTM) of $60.67 million for the quarter ending December 31, 2023, a -88.31% decrease year-over-year.
Maravai LifeSciences Holdings Inc (MRVI) Earnings per Share 2024
MRVI earnings per share (TTM) was -$0.9005 for the quarter ending December 31, 2023, a -154.58% decline year-over-year.
About Maravai LifeSciences Holdings Inc
Maravai LifeSciences Holdings, Inc. operates as a life sciences company that provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in three segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment manufactures and sells products used in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. The Protein Detection segment sells labeling and detection reagents for researchers in immunohistochemistry. The company serves biopharmaceutical companies, and other emerging biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.
Cap:
|
Volume (24h):